PEOPLE - Urologix (US) makes appointment:
This article was originally published in Clinica
Executive Summary
Urologix (Minneapolis, Minnesota), a developer, manufacturer and marketer of minimally invasive medical products for the treatment of urological disorders, has appointed Fred Parks as chairman and CEO. Dr Parks, who most recently served as CEO of Philips Medical Systems (Cleveland, Ohio) following its acquisition of Marconi Medical Systems (where he was also serving as CEO), replaces Michael Selzer, who has resigned as CEO and from the board. The company has also announced that it is reducing its workforce by 26%, including its vice-president and CFO Christopher Geyen. Mr Geyen's responsibilities will be assumed by Todd Paulson.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.